Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 5/20 | 0.57 |
| ▸ | ELANE | P08246 | 5/20 | 0.55 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.51 |
| ▸ | HTT | P42858 | 3/20 | 0.51 |
| ▸ | MAPT | P10636 | 2/20 | 0.51 |
| ▸ | LMNA | P02545 | 1/20 | 0.51 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.51 |
| ▸ | ESR1 | P03372 | 4/20 | 0.46 |
| ▸ | MEN1 | O00255 | 1/20 | 0.45 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.44 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.44 |
| ▸ | HPGD | P15428 | 1/20 | 0.44 |
| ▸ | RECQL | P46063 | 1/20 | 0.44 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.44 |
| ▸ | POLB | P06746 | 1/20 | 0.43 |
| ▸ | SIRT5 | Q9NXA8 | 1/20 | 0.43 |
| ▸ | PARP10 | Q53GL7 | 1/20 | 0.42 |
| ▸ | CES2 | O00748 | 1/20 | 0.42 |
| ▸ | CES1 | P23141 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL522154 | 0.93 | KMT2A (0.58) | KMT2AELANEALDH1A1HTTMAPT | |
| SCHEMBL5711151 | 0.86 | ALDH1A1 (0.57) | KMT2AELANEALDH1A1HTTMAPT | |
| SCHEMBL22666944 | 0.81 | ELANE (0.74) | KMT2AELANEALDH1A1HTTMAPT | |
| SCHEMBL23843934 | 0.78 | KMT2A (0.60) | KMT2AALDH1A1HTTMAPTLMNA | |
| SCHEMBL28340805 | 0.78 | KMT2A (0.66) | KMT2AALDH1A1HTTMAPTLMNA | |
| SCHEMBL43742 | 0.76 | KMT2A (0.61) | KMT2AELANEALDH1A1HTTMAPT | |
| SCHEMBL28370277 | 0.76 | KMT2A (0.58) | KMT2AELANEALDH1A1HTTMAPT | |
| SCHEMBL14276948 | 0.76 | PRSS1 (0.54) | KMT2AELANEALDH1A1HTTMAPT | |
| SCHEMBL29947443 | 0.76 | ALDH1A1 (0.46) | KMT2AELANEALDH1A1HTTMAPT | |
| SCHEMBL18333384 | 0.75 | KMT2A (0.57) | KMT2AALDH1A1HTTMAPTLMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 110 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2121719-A2 | 2-5A DERIVATIVES AND THEIR USE AS ANTI-CANCER, ANTI-VIRAL AND ANTI-PARASITIC AGENTS | Alios Biopharma, Inc. (US) | 2009-11-25 | — | — | EP | claimed |
| WO-2009086192-A1 | BIODEGRADABLE PHOSPHATE PROTECTED NUCLEOTIDE DERIVATIVES AND THEIR USE AS CANCER, ANTI VIRAL AND ANTI PARASITIC AGENTS | ALIOS BIOPHARMA, INC. (US) | 2009-07-09 | — | — | WO | claimed |
| WO-2009086201-A1 | 2-5A ANALOGS AND THEIR USE AS ANTI-CANCER, ANTI-VIRAL AND ANTI- PARAS ITI C AGENTS | ALIOS BIOPHARMA, INC. (US) | 2009-07-09 | — | — | WO | claimed |
| WO-2008095040-A2 | 2-5A DERIVATIVES AND THEIR USE AS ANTI-CANCER, ANTI-VIRAL AND ANTI-PARASITIC AGENTS | ALIOS BIOPHARMA, INC. (US) | 2008-08-07 | — | — | WO | claimed |
| WO-2000004062-A1 | RECOVERY OF TRIARYLMETHYL HALIDE PROTECTING GROUPS CLEAVED DURING OLIGONUCLEOTIDE SYNTHESIS | ISIS PHARMACEUTICALS, INC. (US) | 2000-01-27 | — | — | WO | claimed |
| EP-3160475-B1 | SUBSTITUTED NUCLEOSIDES AND NUCLEOTIDES TO TREAT FILOVIRIDAE INFECTIONS | JANSSEN PHARMACEUTICALS INC (US) | 2024-01-03 | — | — | EP | disclosed |
| EP-3013340-B9 | SUBSTITUTED NUCLEOSIDES, NUCLEOTIDES AND ANALOGS THEREOF | JANSSEN PHARMACEUTICALS INC (US) | 2023-10-04 | — | — | EP | disclosed |
| EP-3013340-B1 | SUBSTITUTED NUCLEOSIDES, NUCLEOTIDES AND ANALOGS THEREOF | JANSSEN BIOPHARMA INC (US) | 2023-06-07 | — | — | EP | disclosed |
| US-20230167151-A1 | SUBSTITUTED NUCLEOSIDES, NUCLEOTIDES AND ANALOGS THEREOF | JANSSEN PHARMACEUTICA NV (BE) | 2023-06-01 | — | — | US | disclosed |
| US-11590155-B2 | Substituted nucleosides, nucleotides and analogs thereof | JANSSEN PHARMACEUTICA NV (BE) | 2023-02-28 | — | — | US | disclosed |
| US-11485753-B2 | Substituted nucleosides, nucleotides and analogs thereof | JANSSEN PHARMACEUTICA NV (BE) | 2022-11-01 | — | — | US | disclosed |
| EP-3912984-A1 | 4'-FLUORO-NUCLEOSIDES, 4'-FLUORO-NUCLEOTIDES AND ANALOGS THEREOF FOR THE TREATMENT OF HCV | Janssen BioPharma, Inc. (US) | 2021-11-24 | — | — | EP | disclosed |
| US-20100240604-A1 | PROTECTED NUCLEOTIDE ANALOGS | ALIOS BIOPHARMA, INC. (US) | 2010-09-23 | — | — | US | disclosed |
| EP-2121719-A2 | 2-5A DERIVATIVES AND THEIR USE AS ANTI-CANCER, ANTI-VIRAL AND ANTI-PARASITIC AGENTS | Alios Biopharma, Inc. (US) | 2009-11-25 | — | — | EP | disclosed |
| US-20090181921-A1 | 2-5A ANALOGS AND THEIR METHODS OF USE | ALIOS BIOPHARMA INC. (US) | 2009-07-16 | — | — | US | disclosed |
| WO-2009086192-A1 | BIODEGRADABLE PHOSPHATE PROTECTED NUCLEOTIDE DERIVATIVES AND THEIR USE AS CANCER, ANTI VIRAL AND ANTI PARASITIC AGENTS | ALIOS BIOPHARMA, INC. (US) | 2009-07-09 | — | — | WO | disclosed |
| WO-2009086201-A1 | 2-5A ANALOGS AND THEIR USE AS ANTI-CANCER, ANTI-VIRAL AND ANTI- PARAS ITI C AGENTS | ALIOS BIOPHARMA, INC. (US) | 2009-07-09 | — | — | WO | disclosed |
| US-20090176732-A1 | PROTECTED NUCLEOTIDE ANALOGS | ALIOS BIOPHARMA INC. (US) | 2009-07-09 | — | — | US | disclosed |
| US-20080207554-A1 | 2-5A Analogs and their Methods of Use | ALIOS BIOPHARMA, INC. (US) | 2008-08-28 | — | — | US | disclosed |
| WO-2008095040-A2 | 2-5A DERIVATIVES AND THEIR USE AS ANTI-CANCER, ANTI-VIRAL AND ANTI-PARASITIC AGENTS | ALIOS BIOPHARMA, INC. (US) | 2008-08-07 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11485753-B2 | Substituted nucleosides, nucleotides and analogs thereof | PNP, NUDT1, NT5C2 | KMT2A 3429/4885ELANE 931/4885ALDH1A1 1431/4885 |
| US-20090176732-A1 | PROTECTED NUCLEOTIDE ANALOGS | NTPCR, NT5C2, PNP | KMT2A 2834/4885ELANE 390/4885ALDH1A1 941/4885 |
| US-20230167151-A1 | SUBSTITUTED NUCLEOSIDES, NUCLEOTIDES AND ANALOGS THEREOF | PNP, NUDT1, NT5C2 | KMT2A 3429/4885ELANE 931/4885ALDH1A1 1431/4885 |
| US-20090181921-A1 | 2-5A ANALOGS AND THEIR METHODS OF USE | RNASEL, RNASE1, RNASEH1 | KMT2A 1495/4885ELANE 447/4885ALDH1A1 1161/4885 |
| US-20100240604-A1 | PROTECTED NUCLEOTIDE ANALOGS | PNP, NTPCR, TYMP | KMT2A 3154/4885ELANE 1296/4885ALDH1A1 3343/4885 |
| US-11590155-B2 | Substituted nucleosides, nucleotides and analogs thereof | PNP, NUDT1, NT5C3B | KMT2A 3185/4885ELANE 683/4885ALDH1A1 2125/4885 |
| US-20080207554-A1 | 2-5A Analogs and their Methods of Use | RNASEL, RNASE1, RNASEH1 | KMT2A 1855/4885ELANE 540/4885ALDH1A1 622/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.